Valuation Update With 7 Day Price Move • 2h
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to ₹41.00, the stock trades at a trailing P/E ratio of 13.3x. Average trailing P/E is 22x in the Chemicals industry in India. Total loss to shareholders of 59% over the past three years. Aankondiging • May 20
MCON Rasayan India Limited to Report Second Half, 2026 Results on May 27, 2026 MCON Rasayan India Limited announced that they will report second half, 2026 results on May 27, 2026 New Risk • May 04
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.9x net interest cover). High level of non-cash earnings (31% accrual ratio). Market cap is less than US$10m (₹410.8m market cap, or US$4.32m). Minor Risk Share price has been volatile over the past 3 months (8.7% average weekly change). Valuation Update With 7 Day Price Move • May 04
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹56.05, the stock trades at a trailing P/E ratio of 18.1x. Average trailing P/E is 23x in the Chemicals industry in India. Total loss to shareholders of 29% over the past three years. Valuation Update With 7 Day Price Move • Apr 06
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to ₹45.70, the stock trades at a trailing P/E ratio of 14.8x. Average trailing P/E is 20x in the Chemicals industry in India. Total loss to shareholders of 48% over the past three years. Valuation Update With 7 Day Price Move • Dec 19
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to ₹72.60, the stock trades at a trailing P/E ratio of 23.5x. Average trailing P/E is 23x in the Chemicals industry in India. Total loss to shareholders of 65% over the past year. Aankondiging • Nov 07
MCON Rasayan India Limited to Report First Half, 2026 Results on Nov 12, 2025 MCON Rasayan India Limited announced that they will report first half, 2026 results on Nov 12, 2025 Valuation Update With 7 Day Price Move • Oct 20
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to ₹63.50, the stock trades at a trailing P/E ratio of 20.5x. Average trailing P/E is 26x in the Chemicals industry in India. Total loss to shareholders of 56% over the past year. Valuation Update With 7 Day Price Move • Sep 25
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to ₹61.65, the stock trades at a trailing P/E ratio of 19.9x. Average trailing P/E is 26x in the Chemicals industry in India. Total loss to shareholders of 61% over the past year. Aankondiging • Sep 01
MCON Rasayan India Limited, Annual General Meeting, Sep 25, 2025 MCON Rasayan India Limited, Annual General Meeting, Sep 25, 2025, at 11:00 Indian Standard Time. Valuation Update With 7 Day Price Move • Aug 05
Investor sentiment deteriorates as stock falls 20% After last week's 20% share price decline to ₹77.65, the stock trades at a trailing P/E ratio of 25x. Average trailing P/E is 28x in the Chemicals industry in India. Total loss to shareholders of 56% over the past year. New Risk • Jun 03
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: ₹834.4m (US$9.75m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.3x net interest cover). High level of non-cash earnings (45% accrual ratio). Market cap is less than US$10m (₹834.4m market cap, or US$9.75m). Minor Risks Share price has been volatile over the past 3 months (8.5% average weekly change). Shareholders have been diluted in the past year (16% increase in shares outstanding). New Risk • Jun 01
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). High level of non-cash earnings (31% accrual ratio). Minor Risks Latest financial reports are more than 6 months old (reported September 2024 fiscal period end). Share price has been volatile over the past 3 months (8.5% average weekly change). Shareholders have been diluted in the past year (16% increase in shares outstanding). Market cap is less than US$100m (₹924.5m market cap, or US$10.8m). Valuation Update With 7 Day Price Move • May 30
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to ₹126, the stock trades at a trailing P/E ratio of 38.3x. Average trailing P/E is 27x in the Chemicals industry in India. Total loss to shareholders of 16% over the past year. New Risk • May 28
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). High level of non-cash earnings (31% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (8.4% average weekly change). Shareholders have been diluted in the past year (16% increase in shares outstanding). Market cap is less than US$100m (₹1.02b market cap, or US$12.0m). Valuation Update With 7 Day Price Move • Apr 18
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹153, the stock trades at a trailing P/E ratio of 46.6x. Average trailing P/E is 25x in the Chemicals industry in India. Total returns to shareholders of 20% over the past year. Valuation Update With 7 Day Price Move • Apr 04
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₹145, the stock trades at a trailing P/E ratio of 44x. Average trailing P/E is 25x in the Chemicals industry in India. Total returns to shareholders of 17% over the past year. Board Change • Mar 06
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Independent Director Tapas Majumdar was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. New Risk • Dec 18
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). High level of non-cash earnings (31% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (7.6% average weekly change). Market cap is less than US$100m (₹1.20b market cap, or US$14.2m). Valuation Update With 7 Day Price Move • Dec 18
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to ₹191, the stock trades at a trailing P/E ratio of 49.9x. Average trailing P/E is 32x in the Chemicals industry in India. Total returns to shareholders of 22% over the past year. Valuation Update With 7 Day Price Move • Nov 22
Investor sentiment deteriorates as stock falls 19% After last week's 19% share price decline to ₹158, the stock trades at a trailing P/E ratio of 41.4x. Average trailing P/E is 31x in the Chemicals industry in India. Total returns to shareholders of 9.2% over the past year. New Risk • Nov 21
New major risk - Financial position The company's debt is not well covered by operating cash flow. Currently running at an operating cash loss. This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). High level of non-cash earnings (31% accrual ratio). Minor Risk Market cap is less than US$100m (₹1.11b market cap, or US$13.1m). New Risk • Nov 06
New minor risk - Revenue size The company makes less than US$5m in revenue. Total revenue: ₹421m (US$5.0m) This is considered a minor risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (30% accrual ratio). Minor Risks High level of debt (97% net debt to equity). Revenue is less than US$5m (₹421m revenue, or US$5.0m). Market cap is less than US$100m (₹1.20b market cap, or US$14.2m). Valuation Update With 7 Day Price Move • Nov 05
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ₹181, the stock trades at a trailing P/E ratio of 51x. Average trailing P/E is 34x in the Chemicals industry in India. Total returns to shareholders of 24% over the past year. Reported Earnings • Aug 23
Full year 2024 earnings released: EPS: ₹3.56 (vs ₹2.63 in FY 2023) Full year 2024 results: EPS: ₹3.56 (up from ₹2.63 in FY 2023). Revenue: ₹421.3m (up 36% from FY 2023). Net income: ₹22.4m (up 97% from FY 2023). Profit margin: 5.3% (up from 3.7% in FY 2023). The increase in margin was driven by higher revenue. Aankondiging • Aug 20
MCON Rasayan India Limited, Annual General Meeting, Sep 12, 2024 MCON Rasayan India Limited, Annual General Meeting, Sep 12, 2024, at 11:00 Indian Standard Time. Valuation Update With 7 Day Price Move • Jun 26
Investor sentiment improves as stock rises 28% After last week's 28% share price gain to ₹182, the stock trades at a trailing P/E ratio of 51.3x. Average trailing P/E is 34x in the Chemicals industry in India. Total returns to shareholders of 72% over the past year. New Risk • Jun 14
New major risk - Financial position The company's interest payments are not well covered by earnings. Net interest cover: 2.8x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.8x net interest cover). Share price has been highly volatile over the past 3 months (10% average weekly change). High level of non-cash earnings (30% accrual ratio). Minor Risk Market cap is less than US$100m (₹904.6m market cap, or US$10.8m). Reported Earnings • May 27
Full year 2024 earnings released: EPS: ₹3.56 (vs ₹2.63 in FY 2023) Full year 2024 results: EPS: ₹3.56 (up from ₹2.63 in FY 2023). Revenue: ₹425.4m (up 37% from FY 2023). Net income: ₹22.4m (up 97% from FY 2023). Profit margin: 5.3% (up from 3.7% in FY 2023). The increase in margin was driven by higher revenue. Valuation Update With 7 Day Price Move • May 19
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to ₹106, the stock trades at a trailing P/E ratio of 43x. Average trailing P/E is 30x in the Chemicals industry in India. Total returns to shareholders of 14% over the past year. New Risk • May 11
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.8% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Share price has been highly volatile over the past 3 months (9.8% average weekly change). High level of non-cash earnings (67% accrual ratio). Market cap is less than US$10m (₹811.6m market cap, or US$9.71m). Minor Risk Revenue is less than US$5m (₹353m revenue, or US$4.2m). Valuation Update With 7 Day Price Move • Mar 01
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to ₹155, the stock trades at a trailing P/E ratio of 62.9x. Average trailing P/E is 30x in the Chemicals industry in India. New Risk • Feb 19
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: ₹827.4m (US$9.96m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). High level of non-cash earnings (67% accrual ratio). Market cap is less than US$10m (₹827.4m market cap, or US$9.96m). Minor Risk Revenue is less than US$5m (₹353m revenue, or US$4.2m). Valuation Update With 7 Day Price Move • Dec 11
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹162, the stock trades at a trailing P/E ratio of 65.8x. Average trailing P/E is 29x in the Chemicals industry in India. Valuation Update With 7 Day Price Move • Oct 25
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to ₹127, the stock trades at a trailing P/E ratio of 70.2x. Average trailing P/E is 27x in the Chemicals industry in India. Reported Earnings • Sep 13
Full year 2023 earnings released: EPS: ₹2.63 (vs ₹1.29 in FY 2022) Full year 2023 results: EPS: ₹2.63 (up from ₹1.29 in FY 2022). Revenue: ₹310.5m (up 62% from FY 2022). Net income: ₹11.4m (up 129% from FY 2022). Profit margin: 3.7% (up from 2.6% in FY 2022). The increase in margin was driven by higher revenue. Valuation Update With 7 Day Price Move • Sep 12
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to ₹138, the stock trades at a trailing P/E ratio of 76.5x. Average trailing P/E is 28x in the Chemicals industry in India. Valuation Update With 7 Day Price Move • Jul 10
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to ₹126, the stock trades at a trailing P/E ratio of 70.1x. Average trailing P/E is 23x in the Chemicals industry in India. Valuation Update With 7 Day Price Move • Jun 06
Investor sentiment improves as stock rises 22% After last week's 22% share price gain to ₹116, the stock trades at a trailing P/E ratio of 64.3x. Average trailing P/E is 21x in the Chemicals industry in India. Reported Earnings • May 31
Full year 2023 earnings released Full year 2023 results: Revenue: ₹310.6m (up 62% from FY 2022). Net income: ₹11.4m (up 156% from FY 2022). Profit margin: 3.7% (up from 2.3% in FY 2022). The increase in margin was driven by higher revenue. Valuation Update With 7 Day Price Move • Apr 04
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ₹54.95, the stock trades at a trailing P/E ratio of 78x. Average trailing P/E is 19x in the Chemicals industry in India. Board Change • Mar 21
High number of new directors There are 6 new directors who have joined the board in the last 3 years. Independent Director Tapas Majumdar was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.